Log In
BCIQ
Print this Print this
 

ImmuFact IMP321 Adjuvant

  Manage Alerts
Collapse Summary General Information
Company Prima BioMed Ltd.
DescriptionLow dose of natural human T cell immunostimulatory factor derived from soluble lymphocyte-activation gene 3 (LAG3; CD223)
Molecular Target Lymphocyte-activation gene 3 (LAG3) (CD223)
Mechanism of Action 
Therapeutic ModalityAdjuvant

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

2

$28.0M

$10.8M

$7.2M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

05/11/2015

Undisclosed

Undisclosed

Undisclosed

12/17/2014

$28.0M

$10.8M

$7.2M

Get a free BioCentury trial today